來 那 度 胺
读音 | /ˌlɛnəˈlɪdoʊmaɪd/ |
---|---|
Revlimid( | |
AHFS/Drugs.com | Monograph |
MedlinePlus | a608001 |
| |
给药 | |
ATC碼 | |
30% | |
药物 | |
3 | |
识别 | |
| |
CAS | 191732-72-6 |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.218.924 |
C13H13N3O3 | |
259.27 g·mol−1 | |
3D | |
| |
|
醫療 用途
[编辑]多發 性 骨髓 瘤
[编辑]骨髓 增 生 異常 症候群
[编辑]被 套細胞 淋巴 瘤
[编辑]輕 鏈澱粉 樣 變性
[编辑]雖然FDA
不良 影響
[编辑]致畸性
[编辑]靜脈 血栓
[编辑]史 蒂芬斯-強 森 症候群
[编辑]FDA於2008
FDA在 進行 中 的 安全 審 查
[编辑]FDA於2011
作用 機 制
[编辑]歷史
[编辑]經濟 學
[编辑]截至2012
參考 文獻
[编辑]- ^ 1.0 1.1 Lenalidomide (Revlimid) Use During Pregnancy. Drugs.com. 2020-03-13 [2020-08-13]. (
原始 内容 存 档于2020-10-09). - ^ LENALIDOMIDE VIATRIS (Alphapharm Pty Ltd). Department of Health and Ages Care. [2023-04-01]. (
原始 内容 存 档于2022-11-13). - ^ Lenalidomide Sun/Lenalidomide Rbx/Lenalidomide Ran (Sun Pharma ANZ Pty Ltd). Department of Health and Ages Care. [2023-04-01]. (
原始 内容 存 档于2023-03-18). - ^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-15]. (
原始 内容 存 档于3 August 2023) (巴 西 葡萄 牙 语). - ^ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 Lenalidomide Monograph for Professionals. Drugs.com. [2019-10-27]. (
原始 内容 存 档于2016-03-04). - ^ 6.0 6.1 6.2 6.3 6.4 DailyMed - Revlimid- lenalidomide capsule. dailymed.nlm.nih.gov. [2019-10-27]. (
原始 内容 存 档于2020-02-16). - ^ World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090 . WHO/MHP/HPS/EML/2023.02.
- ^ Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. Journal of Clinical Pharmacy and Therapeutics. June 2008, 33 (3): 219–26. PMID 18452408. S2CID 1228171. doi:10.1111/j.1365-2710.2008.00920.x .
- ^ 9.0 9.1 Li S, Gill N, Lentzsch S. Recent advances of IMiDs in cancer therapy. Current Opinion in Oncology. November 2010, 22 (6): 579–85. PMID 20689431. S2CID 205547603. doi:10.1097/CCO.0b013e32833d752c.
- ^ Tageja N. Lenalidomide - current understanding of mechanistic properties. Anti-Cancer Agents in Medicinal Chemistry. March 2011, 11 (3): 315–26. PMID 21426296. doi:10.2174/187152011795347487.
- ^ Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A. Mechanism of action of lenalidomide in hematological malignancies. Journal of Hematology & Oncology. August 2009, 2: 36. PMC 2736171 . PMID 19674465. doi:10.1186/1756-8722-2-36 .
- ^ Yang B, Yu RL, Chi XH, Lu XC. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLOS ONE //www.ncbi.nlm.nih.gov/pmc/articles/PMC3653900
|PMC=
缺 少 标题 (帮助). 2013, 8 (5): e64354. Bibcode:2013PLoSO...864354Y. PMC 3653900 . PMID 23691202. doi:10.1371/journal.pone.0064354 . - ^ Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. March 2012, 119 (12): 2764–7. PMID 22323483. doi:10.1182/blood-2011-08-373514 .
- ^ FDA approves lenalidomide oral capsules (Revlimid) for use in combination with dexamethasone in patients with multiple myeloma. U.S. Food and Drug Administration (FDA). 2006-06-29 [2015-10-15]. (
原始 内容 存 档于2011-11-25). - ^ Lenalidomide (Revlimid). U.S. Food and Drug Administration (FDA). 2017-02-22 [2020-08-13]. (
原始 内容 存 档于2020-08-13). - ^ REVLIMID Receives Positive Final Appraisal Determination from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales. Reuters. 2009-04-23. (
原始 内容 存 档于2009-06-24). - ^ Piechotta V, Jakob T, Langer P, Monsef I, Scheid C, Estcourt LJ, et al. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. The Cochrane Database of Systematic Reviews. November 2019, 2019 (11). PMC 6876545 . PMID 31765002. doi:10.1002/14651858.CD013487.
已 忽 略 未知 参 数 |collaboration=
(帮助) - ^ List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. The New England Journal of Medicine. February 2005, 352 (6): 549–57. PMID 15703420. doi:10.1056/NEJMoa041668 .
- ^ List AF. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). Seminars in Oncology. August 2005, 32 (4 Suppl 5): S31–5. PMID 16085015. doi:10.1053/j.seminoncol.2005.06.020.
- ^ List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England Journal of Medicine. October 2006, 355 (14): 1456–65. PMID 17021321. doi:10.1056/NEJMoa061292 .
- ^ Revlimid Approved In Europe For Use In Myelodysplastic Syndromes. The MDS Beacon. [2013-06-17]. (
原始 内容 存 档于2015-09-21). - ^ Revlimid and Amyloidosis AL (PDF). MyelomaUK. [2020-10-03]. (
原始 内容 (PDF)存 档于2021-09-27). - ^ Rao KV. Lenalidomide in the treatment of multiple myeloma. American Journal of Health-System Pharmacy. September 2007, 64 (17): 1799–807. PMID 17724360. doi:10.2146/ajhp070029.
- ^ Revlimid Summary of Product Characteristics. Annex I (PDF). European Medicines Agency: 6. 2012 [2014-04-16]. (
原始 内容 存 档 (PDF)于2014-03-01). - ^ Ness, Stacey. New Specialty Drugs. Pharmacy Times. March 2014 Mental Health. 2014-03-13, 80 (3) [2015-11-05]. (
原始 内容 存 档于2015-09-21). - ^ Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. December 2006, 296 (21): 2558–60. PMID 17148721. doi:10.1001/jama.296.21.2558-c.
- ^ Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between January - March 2008. U.S. Food and Drug Administration. March 2008 [2019-12-16]. (
原始 内容 存 档于2014-04-19). - ^ 28.0 28.1 Badros AZ. Lenalidomide in myeloma--a high-maintenance friend. The New England Journal of Medicine. May 2012, 366 (19): 1836–8. PMID 22571206. doi:10.1056/NEJMe1202819.
- ^ FDA Drug Safety Communication: Ongoing safety review of Revlimid (lenalidomide) and possible increased risk of developing new malignancies. U.S. Food and Drug Administration (FDA). April 2011 [2020-08-13]. (
原始 内容 存 档于2020-08-13). - ^ Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leukemia & Lymphoma. July 2008, 49 (7): 1238–45. PMID 18452080. S2CID 43350339. doi:10.1080/10428190802005191.
- ^ Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. November 2011, 118 (18): 4771–9. PMC 3208291 . PMID 21860026. doi:10.1182/blood-2011-05-356063.
- ^ Stewart AK. Medicine. How thalidomide works against cancer. Science. January 2014, 343 (6168): 256–7. PMC 4084783 . PMID 24436409. doi:10.1126/science.1249543.
- ^ Top 10 Best-Selling Cancer Drugs of 2018. Genetic Engineering and Biotechnology News. 2019-04-22 [2019-04-25]. (
原始 内容 存 档于2019-04-23). - ^ Jensen, Chelsee. The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable. Journal of Managed Care·Speciality Pharmacy. September 2021, 27 (9) [2024-01-10]. doi:10.18553/jmcp.2021.27.9.1321.
- ^ Revlimid faces NICE rejection for use in rare blood cancer Watchdog's draft guidance does not recommend Celgene's drug for NHS use in England and Wales. Pharma News. 2013-07-11 [2015-11-05]. (
原始 内容 存 档于2016-02-13). - ^ Care, Australian Government Department of Health and Aged, Pharmaceutical Benefits Scheme (PBS) |, Australian Government Department of Health and Aged Care, [31 March 2023], (
原始 内容 存 档于2023-03-31)